Open Access<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>
Author(s) -
Li Chen,
Xiangyi Kong,
Zhongzhao Wang,
Xiangyu Wang,
Yi Fang,
Jing Wang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s235519
Subject(s) - medicine , breast cancer , proportional hazards model , oncology , chemotherapy , univariate analysis , cancer , multivariate analysis , receiver operating characteristic
Systemic inflammation response index (SIRI=N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to predict the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition. The present study is aimed to evaluate the potential prognostic significance of SIRI in patients with breast cancer undergoing neoadjuvant chemotherapy.